[{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"OncoX BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"ABV-1519","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"ABVC BioPharma \/ OncoX BioPharma","highestDevelopmentStatusID":"7","companyTruncated":"ABVC BioPharma \/ OncoX BioPharma"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"AiBtl BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ AiBtl BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ AiBtl BioPharma"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"OncoX BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"ABV-1519","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"ABVC BioPharma \/ OncoX BioPharma","highestDevelopmentStatusID":"7","companyTruncated":"ABVC BioPharma \/ OncoX BioPharma"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Wilmington Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Grifola Frondosa Maitake Mushroom Extract","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABVC BioPharma \/ Wilmington Capital Securities","highestDevelopmentStatusID":"7","companyTruncated":"ABVC BioPharma \/ Wilmington Capital Securities"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"The Lind Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Financing","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ The Lind Partners","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ The Lind Partners"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Xinnovation Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Xinnovation Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Xinnovation Therapeutics"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"AiBtl BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Licensing Agreement","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ AiBtl BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ AiBtl BioPharma"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"AiBtl BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ AiBtl BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ AiBtl BioPharma"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"ForSeeCon Eye Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"ABV-1701","moa":"Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ABVC BioPharma \/ ForSeeCon Eye Corporation","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ ForSeeCon Eye Corporation"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"BIOKEY","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BLEX 404","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ABVC BioPharma \/ BIOKEY","highestDevelopmentStatusID":"5","companyTruncated":"ABVC BioPharma \/ BIOKEY"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"BioLite","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ BioLite","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ BioLite"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"BioLite","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ BioLite","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ BioLite"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ University of California"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ University of California"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Grifola Frondosa Extract","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ABVC BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by ABVC BioPharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : ABVC would grant OncoX an exclusive global rights to develop and commercialize its oncology/hematology pipeline, including ABV-1519 for triple negative breast cancer, ABV-1501 for NSCLC.

                          Product Name : BLEX 404

                          Product Type : Other Large Molecule

                          Upfront Cash : $100.0 million

                          October 04, 2024

                          Lead Product(s) : ABV-1519,Docetaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : OncoX BioPharma

                          Deal Size : $105.0 million

                          Deal Type : Licensing Agreement

                          blank

                          02

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : ABVC grants OncoX exclusive rights for BLEX 404 (ABV-1519), a promising therapeutic agent for NSCLC, under a collaboration agreement.

                          Product Name : BLEX 404

                          Product Type : Other Large Molecule

                          Upfront Cash : $13.7 million

                          April 17, 2024

                          Lead Product(s) : ABV-1519,Cisplatin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : OncoX BioPharma

                          Deal Size : $26.2 million

                          Deal Type : Licensing Agreement

                          blank

                          03

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Under the agreement, ForSeeCon gains access to ABVC's ophthalmology pipeline, which includes the device Vitargus, the first biodegradable vitreous substitute facilitating retinal reattachment surgery.

                          Product Name : Vitargus

                          Product Type : Other Small Molecule

                          Upfront Cash : $33.5 million

                          March 26, 2024

                          Lead Product(s) : ABV-1701

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : ForSeeCon Eye Corporation

                          Deal Size : $93.5 million

                          Deal Type : Licensing Agreement

                          blank

                          04

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : ABVC has out-licensed CNS drugs for MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder), including ABV-1504, a botanical reuptake inhibitor for MDD.

                          Product Name : ABV-1504

                          Product Type : Other Small Molecule

                          Upfront Cash : $7.0 million

                          March 01, 2024

                          Lead Product(s) : Polygala Tenuifolia Extract

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : AiBtl BioPharma

                          Deal Size : $667.0 million

                          Deal Type : Licensing Agreement

                          blank

                          05

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : PDC-1421 (radix polygalae extract) is a drug product of ABV-1504, it is a botanical-based Norepinephrine Transporter (NET) inhibitor, it is being indicated for treatment of Attention-deficit/hyperactivity disorder.

                          Product Name : ABV-1505

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          December 06, 2023

                          Lead Product(s) : Radix Polygalae Extract

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : BioLite

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Under the agreement, ABVC out-licenses its CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder), including ABV-1504, a botanical reuptake inhibitor for MDD.

                          Product Name : ABV-1504

                          Product Type : Other Small Molecule

                          Upfront Cash : $7.0 million

                          November 16, 2023

                          Lead Product(s) : Polygala Tenuifolia Extract

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : AiBtl BioPharma

                          Deal Size : $667.0 million

                          Deal Type : Licensing Agreement

                          blank

                          07

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Under the agreement, ABVC licenses its CNS drugs, ABV-1504 and ABV-1505 with the indications of Major Depressive Disorder and Attention Deficit Hyperactivity Disorder, respectively, to AiBtl BioPharma.

                          Product Name : ABV-1505

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : $7.0 million

                          October 26, 2023

                          Lead Product(s) : Radix Polygalae Extract

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : AiBtl BioPharma

                          Deal Size : $207.0 million

                          Deal Type : Licensing Agreement

                          blank

                          08

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : ABV-1505 (PDC-1421) is a norepinephrine transporter (NET) inhibitor indicated for attention deficit hyperactivity disorder (ADHD). It has demonstrating a highly significant 13.2-point reduction in depression as compared to a 9.2-point reduction for the p...

                          Product Name : ABV-1505

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          October 17, 2023

                          Lead Product(s) : Radix Polygalae Extract

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.), it is being investigated for the treatment of major depressive disorder.

                          Product Name : PDC-1421

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 04, 2023

                          Lead Product(s) : Polygala Tenuifolia Extract

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : PDC-1421 (radix polygalae extract) is a norepinephrine transporter (NET) inhibitor indicated for attention deficit hyperactivity disorder (ADHD). It has demonstrating a highly significant 13.2-point reduction in depression as compared to a 9.2-point redu...

                          Product Name : ABV-1505

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          August 23, 2023

                          Lead Product(s) : Radix Polygalae Extract

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank